Dr. Agarwal's Health Care Limited: A Vision for Growth in Q3 & 9M FY26

Dr. Agarwal's Health Care Limited, a leading name in India's eye care services industry, recently announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company has demonstrated a robust performance, reflecting sustained execution momentum across its expansive network. For the nine-month period, the total income surged to INR 1,548 crore, marking a significant 20.8% year-on-year growth. This financial uplift was complemented by a strong operational showing, with revenue from operations rising 21.2% to INR 1,516 crore.

The company's profitability metrics also saw substantial improvement. IndAS EBITDA grew by 23.6% year-on-year to INR 440 crore, with EBITDA margins expanding to 28.4%. The profit after tax (PAT) witnessed an impressive 74.3% increase, reaching INR 118 crore, and PAT margins improved to 7.6%. This strong financial health underscores the resilience of the operating model and disciplined cost management practices employed by the company. The management expressed confidence in meeting its annual guidance, supported by resilient demand and strong momentum in its expansion plans.

Operational Excellence and Strategic Expansion

Dr. Agarwal's Health Care Limited continues to solidify its position as India's largest eye care service chain. As of December 31, 2025, the company's network comprised 272 facilities across 14 states and 5 Union Territories in India, and 19 facilities across nine countries in Africa. This diversified presence, with 84 facilities in Tier-I cities and 169 in other cities, highlights its extensive reach.

During the nine-month period, the company added 38 new centers, including 14 Greenfield facilities commissioned in Q3 FY26 alone. These additions comprised 9 secondary and 5 primary facilities. The management noted that the ramp-up across recently launched facilities has been faster than earlier phases, bolstered by strengthening brand equity. This reinforces their confidence in scaling expansion more aggressively while continuing to deliver superior clinical outcomes. The company's strategic focus remains on accelerating organic growth through aggressive greenfield expansion, deepening its presence in existing markets, and selectively entering newer geographies.

Financial Summary (9M FY26, Consolidated)

Driving Growth Through Innovation and Talent

The company's revenue mix for the nine months ending December 2025 demonstrates a strong reliance on surgical services, which contributed 67.0% of the total revenue from operations. Opticals, contact lenses, and accessories accounted for 13.1%, while diagnosis, consultations, and other non-surgical treatments contributed 11.6%. Eye care related pharmaceutical products made up the remaining 8.4%.

Dr. Agarwal's Health Care Limited continues to invest heavily in cutting-edge technology to enhance diagnostic accuracy and surgical outcomes. Recent technological additions include CATALYS and ELITA Systems at the Gurgaon center, and LUMERA 300 and ORTELI FAROS at the Preet Vihar center. New robotic cataract systems have been installed at the Velachery facility in Chennai and the Delhi facility, significantly boosting high-end cataract procedures. For instance, Femto cataract surgeries grew by a robust 83% year-on-year, rising from 2,616 to 4,400 procedures, contributing significantly to value accretion.

Revenue Mix by Product (YTD Dec-25)

Beyond technology, the company places a strong emphasis on empowering its medical professionals. It has 18 ongoing clinical research studies and its clinicians have contributed to over 340 peer-reviewed publications over the past three decades. During the quarter, nearly 50 doctors underwent advanced training across multiple specialties as part of continuous learning and development initiatives. This commitment to talent and innovation ensures high standards of patient safety and clinical quality across its network.

Strategic Outlook and Future Initiatives

Looking ahead, Dr. Agarwal's Health Care Limited has outlined clear growth strategies. The company aims to add anywhere between 55 to 60 facilities every year, with a plan to launch another 16 centers in the next quarter of FY26, including 11 surgical centers. New facilities in core markets are expected to break even within six to seven months, while those in newer regions typically take 15 to 18 months. The company is also expanding its international footprint, with the incorporation of a wholly owned subsidiary in Ethiopia, a market identified for its high potential and cash revenue mix.

Furthermore, the Board has approved a scheme of amalgamation with its subsidiary, Dr. Agarwal's Eye Hospital Limited (AEHL), which is expected to be completed by Q3-Q4 FY27. This move aims to streamline the corporate structure and operations. The company also proactively addressed the impact of new labor codes, aligning its existing salary structures and employee benefit policies, with no material current impact. This forward-thinking approach, coupled with robust financial performance and a clear expansion roadmap, positions Dr. Agarwal's Health Care Limited for continued leadership and sustainable growth in the evolving eye care landscape.